uniQure prepares for FDA Type A meeting on AMT-130

An update from uniQure ( (QURE) ) is now available.

On January 9, 2026, uniQure announced that the U.S. Food and Drug Administration has scheduled a Type A meeting with the company to discuss the Biologics License Application data package supporting a potential accelerated approval of AMT-130, its investigational gene therapy for Huntington’s disease. Management highlighted the significant unmet medical need in the Huntington’s disease community and its commitment to timely patient access, signaling that a favorable regulatory outcome could be a key milestone for uniQure’s Huntington’s program and broader gene therapy pipeline; the company plans to issue a regulatory update after it receives the FDA’s official meeting minutes.

The most recent analyst rating on (QURE) stock is a Buy with a $60.00 price target. To see the full list of analyst forecasts on uniQure stock, see the QURE Stock Forecast page.

Spark’s Take on QURE Stock

According to Spark, TipRanks’ AI Analyst, QURE is a Neutral.

uniQure’s overall stock score is primarily impacted by its financial performance and technical analysis, both of which indicate significant challenges. The company’s negative profitability and bearish technical indicators weigh heavily on the score. The earnings call provides some optimism with advancements in the therapeutic pipeline, but regulatory setbacks and increased costs remain concerns.

To see Spark’s full report on QURE stock, click here.

More about uniQure

uniQure N.V., listed on Nasdaq under the ticker QURE, is a gene therapy company focused on developing single-treatment, potentially curative therapies for patients with severe medical needs. Building on the approval of its gene therapy for hemophilia B, the company is advancing a pipeline of proprietary gene therapies targeting Huntington’s disease, refractory temporal lobe epilepsy, ALS, Fabry disease and other serious conditions, positioning itself in the forefront of genomic medicine.

Average Trading Volume: 3,124,912

Technical Sentiment Signal: Buy

Current Market Cap: $1.42B

For an in-depth examination of QURE stock, go to TipRanks’ Overview page.